-
-
-
-
-
-
-
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
-
-
-
-
-
-
-
TuHURA Biosciences receives FDA orphan drug designation for melanoma treatment
-
-
-
-
-
-
-
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
-
-
-
-
-
-
-
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
TuHURA Biosciences (HURA) and Kineta (KANT) Receive Stockholders Approval of Proposed Merger and All Related Proposals
-
-
-
-
-
-
-
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
TuHURA Biosciences (HURA) Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
-
1,155,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

